Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 128

Results For "cost"

1275 News Found

Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business


LASA receives WHO nod for its Ratnagiri unit
Policy | January 13, 2021

LASA receives WHO nod for its Ratnagiri unit

Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.


Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn
News | January 08, 2021

Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn

Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.


Aditya Puri joins as director of Stelis Biopharma
People | January 08, 2021

Aditya Puri joins as director of Stelis Biopharma

Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.